Exploring termination setback in a psychodynamic therapy for panic disorder

OBJECTIVE: Termination in psychodynamic therapy (PDT) is a potentially conflictual and turbulent phase for patients, with a risk for increases in symptoms. However, few studies of PDT have assessed symptoms frequently enough during the treatment to determine whether such setbacks are in fact common in PDT.

METHOD: In a doubly randomized clinical preference trial, 217 adults, female = 163; M age = 34.8 (12.6), with panic disorder with or without agoraphobia were treated with panic-focused psychodynamic psychotherapy (PFPP) or panic control treatment (PCT), a form of cognitive behavioral therapy. Participants completed the Panic Disorder Severity Scale Self-Report (PDSS-SR) weekly during treatment (Weeks 1-12), and 6, 12, and 24 months after treatment. Using piecewise latent growth curve modeling, we tested the trajectories of change focusing on the termination phase in PFPP.

RESULTS: Week-to-week improvement on the PDSS-SR stopped (a termination setback [TS]) in PFPP during Weeks 10-12, whereas PCT participants continued to improve. Larger symptom reductions up to Week 10 in PFPP predicted a more severe TS. Less avoidant attachment and less severe interpersonal problems also predicted more severe TS. The TSs tended to last, as evidenced by inferior outcomes, up to the 12-month follow-up.

CONCLUSIONS: This study provides evidence of a TS in PDT. Resurgence of symptoms as termination approached was more common in PFPP than in PCT. Studies involving weekly assessment of primary and comorbid symptoms, as well as qualitative analyses of the patient experiences of the therapeutic process during termination, in different forms of PDT, are warranted. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:89

Enthalten in:

Journal of consulting and clinical psychology - 89(2021), 9 vom: 13. Sept., Seite 762-772

Sprache:

Englisch

Beteiligte Personen:

Nilsson, Thomas [VerfasserIn]
Falkenström, Fredrik [VerfasserIn]
Perrin, Sean [VerfasserIn]
Svensson, Martin [VerfasserIn]
Johansson, Håkan [VerfasserIn]
Sandell, Rolf [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
Randomized Controlled Trial

Anmerkungen:

Date Completed 25.11.2021

Date Revised 25.11.2021

published: Print

ClinicalTrials.gov: NCT01606592

Citation Status MEDLINE

doi:

10.1037/ccp0000678

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM331330113